The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors.
P. Schoffski
Research Funding - ImClone Systems; Lilly
D. Adkins
Honoraria - ImClone Systems
J. Blay
Consultant or Advisory Role - ARIAD; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Honoraria - ARIAD; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar; Roche
Research Funding - ARIAD; GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - Takeda
T. Gil
No relevant relationships to disclose
A. D. Elias
No relevant relationships to disclose
P. Rutkowski
No relevant relationships to disclose
G. K. Pennock
Honoraria - Bristol-Myers Squibb; Lilly
H. Youssoufian
Employment or Leadership Position - ImClone Systems; ImClone Systems
Stock Ownership - Lilly
N. J. Zojwalla
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
R. Willey
Employment or Leadership Position - ImClone Systems
D. O. Grebennik
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly